However, HA can cause some risks of clot formation when administered intra- venously,16–21 even if it was reported that injections up to 0.75 mg/mL could be safe.14SUL is a known mixture of GAGs, which is already used clinically for vascular treatments.22 It has specific pharmacological features, and the anticoagulant ability is one of them. SUL, in fact, interferes with the mech- anisms that control the platelet aggregation and, there- fore, the coagulation of the corpuscle components in the circulating blood. Sclerotherapy involves the use of sclerosants, POL or STS, with the aim of damaging